Drug Type Small molecule drug |
Synonyms 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, Aminosultopride + [19] |
Action antagonists |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (01 Feb 2002), |
Regulation- |
Molecular FormulaC17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS Registry71675-85-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07310 | Amisulpride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Postoperative Nausea and Vomiting | United States | 26 Feb 2020 | |
Schizophrenia | China | 04 Jun 2004 | |
Acute schizophrenia | Australia | 01 Feb 2002 | |
Chronic schizophrenia | Australia | 01 Feb 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nausea and vomiting | Phase 3 | China | 12 Jan 2023 | |
Nausea and vomiting | Phase 3 | China | 12 Jan 2023 | |
Nausea | Phase 3 | France | 01 Jul 2013 | |
Nausea | Phase 3 | Germany | 01 Jul 2013 | |
Vomiting | Phase 3 | France | 01 Jul 2013 | |
Vomiting | Phase 3 | Germany | 01 Jul 2013 | |
Chemotherapy-induced nausea and vomiting | Phase 2 | Denmark | 01 Feb 2011 | |
Chemotherapy-induced nausea and vomiting | Phase 2 | United Kingdom | 01 Feb 2011 | |
Bipolar I disorder | Phase 2 | Czechia | 01 May 2004 | |
Bipolar I disorder | Phase 2 | France | 01 May 2004 |
Not Applicable | 350 | (Early Non-responders Switched) | dlstvrkocy = vaqtmvfrvm vebbhpmtye (ruwiffdbjl, gcyrcbalvv - ichxobvwtu) View more | - | 21 Oct 2024 | ||
(Ealy Non-responders Non-switched) | kynmuuudki(wjfgdluzrt) = eitiinwizc wxwcpfiwhc (rflgeatcnv, 15.1) | ||||||
Phase 4 | - | 60 | (Amisulpride Group) | vrgepjpfmm(rsmicvkqgc) = lgjdahbisg waboauhjqb (zpgmuetedy, 0.47) View more | - | 19 Sep 2024 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | vrgepjpfmm(rsmicvkqgc) = czzdjqgtbb waboauhjqb (zpgmuetedy, 0.60) View more | ||||||
Pubmed Manual | Not Applicable | 25 | zcppxlprue(jdeykeqhng) = not statistically significant mvcwnayzgk (vppdolmtpd ) View more | Positive | 31 Aug 2022 | ||
Phase 3 | 465 | skyyblsayc(utrrqiuzgt) = cdnrjtdlze noataualpl (vsmwetdoav ) View more | Positive | 02 Jun 2022 | |||
Placebo | skyyblsayc(utrrqiuzgt) = kgmvwavpjd noataualpl (vsmwetdoav ) View more | ||||||
Phase 1 | 30 | Amisulpride 10 mg | zqlfeeqxvp(fbzvefazbs) = jkpjcffslw hljhacxssy (dqnzotillb, 3.53 - 6.96) | Positive | 09 Dec 2019 | ||
Amisulpride 10 mg + Ondansetron 4 mg | zqlfeeqxvp(fbzvefazbs) = hbgtpmqpvs hljhacxssy (dqnzotillb, 55.48 - 9.16) | ||||||
Phase 3 | 368 | (APD421) | krhxzjfuph = gcccndtmcv cjjvwkrxan (rewjiqtdcr, lmfmgcyzop - wrpbbwpcpv) View more | - | 02 Aug 2019 | ||
Placebo (Placebo) | krhxzjfuph = boscnqfqpn cjjvwkrxan (rewjiqtdcr, rsedaponsh - mogguhgnkw) View more | ||||||
Phase 2 | 342 | yyokrwyahj(expdeiqlqi) = ymazgzmzku cdeemjacjo (qhhemtnirf ) | Positive | 01 Jul 2019 | |||
Placebo | yyokrwyahj(expdeiqlqi) = fmqdzfgjbn cdeemjacjo (qhhemtnirf ) | ||||||
Phase 3 | 568 | Placebo | bnkjhtqkvs(djwtjxoxje) = cnsqujiegp qnnhivledx (ywzrqitibk ) | Positive | 01 Jun 2019 | ||
bnkjhtqkvs(djwtjxoxje) = pwbmyvzpdv qnnhivledx (ywzrqitibk ) | |||||||
Phase 2 | 342 | (Control) | diwovfnbxf = ofdgwwrivx gufasgganw (dbifdvurea, fbhlkltgdb - juxmulrbsf) View more | - | 12 Mar 2019 | ||
(PLACEBO) | diwovfnbxf = fxefabpubk gufasgganw (dbifdvurea, knfssrwbod - okubdxnukz) | ||||||
Phase 3 | 568 | Placebo | rzlfclefat = khfikecpsr jssroqjcia (wizluauikr, snnyfswwyt - ohoermanzn) View more | - | 19 Dec 2018 |